Glucopet (Fludeoxyglucose (18f))

Glucopet is employed as a diagnostic agent in PET scans that evaluate tissue metabolism across several clinical specialties.

• Oncologic PET imaging for detection, staging, and monitoring of malignant tumors.
• Cardiac PET imaging to assess myocardial perfusion and viability.
• Neurologic PET imaging for investigation of epilepsy, dementia, and brain metabolism.
• Evaluation of therapeutic response in cancer patients undergoing treatment.
• Research use in metabolic studies and drug development trials.

Adverse reactions to Glucopet are generally mild and transient, but rare serious events have been reported.

Common

• Mild nausea or vomiting shortly after injection.
• Temporary flushing or warmth sensation at the injection site.
• Short‑lasting headache or dizziness.

Serious

• Severe allergic reaction such as anaphylaxis.
• Acute hypotension or cardiovascular collapse.
• Persistent vomiting or severe gastrointestinal upset requiring medical attention.

Glucopet should be administered by qualified personnel in facilities equipped for radiopharmaceutical handling.

• Verify patient identity and indication before injection.
• Assess for known hypersensitivity to fluorodeoxyglucose or similar compounds.
• Use appropriate radiation safety measures to protect staff and other patients.
• Consider renal function, as impaired clearance may affect tracer distribution.
• Pregnant or breastfeeding patients should be evaluated carefully due to unknown fetal exposure.
• Document and monitor vital signs during and after administration.

Glucopet may interact with other agents that influence glucose metabolism or radiation exposure.

Avoid

• Concurrent administration of high‑dose glucose or insulin that could alter tracer uptake.
• Use of other radiopharmaceuticals within a short interval that may cause cumulative radiation dose.

Use with caution

• Medications that affect blood glucose levels, such as oral hypoglycemics.
• Contrast agents used in CT imaging performed shortly before or after PET.
• Drugs that modify cellular metabolism, including certain chemotherapeutic agents.